C. Valsuani

456 total citations
16 papers, 248 citations indexed

About

C. Valsuani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, C. Valsuani has authored 16 papers receiving a total of 248 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in C. Valsuani's work include Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Treatments and Mutations (6 papers). C. Valsuani is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Treatments and Mutations (6 papers). C. Valsuani collaborates with scholars based in Italy, Brazil and Japan. C. Valsuani's co-authors include Sara Donati, Andrea Camerini, D. Amoroso, G. Tartarelli, C. Puccetti, Luca Boni, Alfredo Falcone, Fotios Loupakis, C. Boni and Chiara Cremolini and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and BMC Cancer.

In The Last Decade

C. Valsuani

16 papers receiving 246 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Valsuani Italy 9 200 105 63 54 49 16 248
Krassimir Koynov Bulgaria 6 195 1.0× 114 1.1× 35 0.6× 35 0.6× 47 1.0× 12 242
Maria Aurelia Barbera Italy 9 134 0.7× 70 0.7× 104 1.7× 53 1.0× 69 1.4× 19 284
Shumei Jiang China 12 162 0.8× 64 0.6× 42 0.7× 92 1.7× 95 1.9× 29 333
Sara E. Stevens United States 7 116 0.6× 168 1.6× 20 0.3× 50 0.9× 80 1.6× 7 226
Cosimo Martino Italy 10 151 0.8× 83 0.8× 12 0.2× 50 0.9× 54 1.1× 18 212
Uriel Bohn Spain 9 144 0.7× 85 0.8× 25 0.4× 68 1.3× 33 0.7× 16 253
Yau H. Yu Hong Kong 2 164 0.8× 277 2.6× 83 1.3× 66 1.2× 104 2.1× 2 331
Ignacio Tusquets Spain 9 131 0.7× 110 1.0× 11 0.2× 59 1.1× 50 1.0× 16 252
Antonio Pellino Italy 6 118 0.6× 85 0.8× 23 0.4× 59 1.1× 56 1.1× 10 224

Countries citing papers authored by C. Valsuani

Since Specialization
Citations

This map shows the geographic impact of C. Valsuani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Valsuani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Valsuani more than expected).

Fields of papers citing papers by C. Valsuani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Valsuani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Valsuani. The network helps show where C. Valsuani may publish in the future.

Co-authorship network of co-authors of C. Valsuani

This figure shows the co-authorship network connecting the top 25 collaborators of C. Valsuani. A scholar is included among the top collaborators of C. Valsuani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Valsuani. C. Valsuani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Camerini, Andrea, C. Puccetti, Sara Donati, et al.. (2015). Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer. 15(1). 359–359. 61 indexed citations
2.
Cremolini, Chiara, Fotios Loupakis, Lisa Salvatore, et al.. (2014). Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.. Journal of Clinical Oncology. 32(15_suppl). 3596–3596. 5 indexed citations
3.
Loupakis, Fotios, Chiara Cremolini, Sara Lonardi, et al.. (2014). Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.. Journal of Clinical Oncology. 32(15_suppl). 3519–3519. 13 indexed citations
4.
Camerini, Andrea, C. Puccetti, Sara Donati, et al.. (2014). Phase Ii Trial of Metronomic Oral Vinorelbine As First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer (Move Trial). Annals of Oncology. 25. iv442–iv442. 1 indexed citations
5.
Salvatore, Lisa, Gianluca Masi, Fotios Loupakis, et al.. (2013). Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Receiving a First-Line Treatment Containing Bevacizumab: Update of Bebyp Trial by Gono. Annals of Oncology. 24. iv22–iv22. 2 indexed citations
6.
7.
Falcone, Alfredo, Chiara Cremolini, Gianluca Masi, et al.. (2013). FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.. Journal of Clinical Oncology. 31(15_suppl). 3505–3505. 47 indexed citations
8.
Loupakis, Fotios, Chiara Cremolini, Gianluca Masi, et al.. (2013). FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.. Journal of Clinical Oncology. 31(4_suppl). 336–336. 23 indexed citations
9.
10.
Camerini, Andrea, Sara Donati, Paolo Viacava, et al.. (2011). Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer. Journal of Experimental & Clinical Cancer Research. 30(1). 38–38. 13 indexed citations
11.
Camerini, Andrea, Ornella Garrone, C. Valsuani, et al.. (2009). Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone receptor-positive metastatic breast cancer patients. Cancer Biology & Therapy. 8(15). 1450–1455. 2 indexed citations
12.
Camerini, Andrea, C. Valsuani, Francesca Mazzoni, et al.. (2009). Phase II trial of single-agent oral vinorelbine in elderly (≥70 years) patients with advanced non-small-cell lung cancer and poor performance status. Annals of Oncology. 21(6). 1290–1295. 18 indexed citations
13.
Valsuani, C., Andrea Camerini, Maria Laura Canale, et al.. (2009). Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report. Cases Journal. 2(1). 9133–9133. 2 indexed citations
14.
Camerini, Andrea, Ornella Garrone, C. Valsuani, et al.. (2009). Effect of fulvestrant treatment on serum VEGF levels in hormone-sensitive metastatic breast cancer patients. Journal of Clinical Oncology. 27(15_suppl). 1124–1124. 1 indexed citations
15.
Amoroso, D., Sara Donati, C. Valsuani, et al.. (2009). Combination of trastuzumab, oxaliplatin, and docetaxel as first-line treatment in HER2-positive metastatic breast cancer patients: First-step results of a phase II trial (HOT trial). Journal of Clinical Oncology. 27(15_suppl). 1132–1132. 2 indexed citations
16.
Sgambato, Alessandro, Andrea Camerini, D. Amoroso, et al.. (2007). Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma. Cancer Biology & Therapy. 6(12). 1840–1846. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Krassimir Koynov Breakdown of academic impact, for papers by Maria Aurelia Barbera Breakdown of academic impact, for papers by Shumei Jiang Breakdown of academic impact, for papers by Sara E. Stevens Breakdown of academic impact, for papers by Cosimo Martino Breakdown of academic impact, for papers by Uriel Bohn Breakdown of academic impact, for papers by Yau H. Yu Breakdown of academic impact, for papers by Ignacio Tusquets Breakdown of academic impact, for papers by Antonio Pellino
Rankless by CCL
2026